Search

Displaying results 1651 - 1660 of 2674 in total
  1. Drug

    Norgestimate

    go.drugbank.com/drugs/DB00957
    ApprovedInvestigational

    [L11845,L11848] Norgestimate was granted FDA approval on 29 December 1989.[L11842]

  2. Drug

    Pindolol

    go.drugbank.com/drugs/DB00960
    ApprovedInvestigational

    [A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348]

    Categories: Serotonin Receptor Antagonists, Serotonin 5-HT1 Receptor Antagonists
  3. Drug

    Enoxaparin

    go.drugbank.com/drugs/DB01225
    ApprovedInvestigational

    Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.

  4. Drug

    Ezogabine

    go.drugbank.com/drugs/DB04953
    ApprovedWithdrawn

    FDA approved in June 10, 2011 under the name of ezogabine.

  5. Drug

    Carglumic acid

    go.drugbank.com/drugs/DB06775
    ApprovedInvestigational

    Food and Drug Administration (FDA) on 18 March 2010.

  6. Drug

    Ganirelix

    go.drugbank.com/drugs/DB06785
    ApprovedInvestigational

    [A252195] Ganirelix was first approved by the FDA on July 29, 1999.[L43070]

    Categories: Gonadotropin Releasing Hormone Receptor Antagonists
  7. Drug

    Maraviroc

    go.drugbank.com/drugs/DB04835
    ApprovedInvestigational

    It was approved for use by the FDA in August, 2007. … Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the

    Categories: CCR5 Receptor Antagonists, CCR5 Co-receptor Antagonist
  8. Drug

    Perampanel

    go.drugbank.com/drugs/DB08883
    ApprovedInvestigational

    The FDA label includes an important black-boxed warning of serious or life-threatening behavioral and psychiatric reactions in patients taking Fycompa™. … Perampanel is a noncompetitive AMPA glutamate receptor antagonist.

    Categories: AMPA Receptor Antagonists, Noncompetitive AMPA Glutamate Receptor Antagonist
  9. Drug

    Elapegademase

    go.drugbank.com/drugs/DB14712
    Approved

    [F1937] Elapegademase is generated in _E. coli_, developed by Leadiant Biosciences and FDA approved on October 5, 2018.[L4654,F1939]

  10. Drug

    Plozasiran

    go.drugbank.com/drugs/DB18997
    ApprovedInvestigational

    [L45864] Plozasiran was first approved by the FDA on November 18th, 2025, to reduce triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS).[L54603]